CARGO THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.72 USD | -2.68% |
|
-6.90% | -27.78% |
Valuation
| Fiscal Period: December | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|
| Capitalization 1 | 953.9 | 658.4 | - | - |
| Enterprise Value (EV) 1 | 953.9 | 658.4 | 658.4 | 658.4 |
| P/E ratio | -1.4 x | -3.47 x | -3.15 x | -3.68 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | 529 x | 6.17 x |
| EV / Revenue | - | - | 529 x | 6.17 x |
| EV / EBITDA | -1,00,17,948 x | - | - | - |
| EV / FCF | -10.7 x | -3.47 x | -3.09 x | -3.49 x |
| FCF Yield | -9.38% | -28.8% | -32.4% | -28.6% |
| Price to Book | - | - | - | - |
| Nbr of stocks (in thousands) | 41,205 | 39,376 | - | - |
| Reference price 2 | 23.15 | 16.72 | 16.72 | 16.72 |
| Announcement Date | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 1.245 | 106.8 |
| EBITDA | - | -95.22 | - | - | - |
| EBIT 1 | - | -96.71 | -211.1 | -247.2 | -193.9 |
| Operating Margin | - | - | - | -19,858.47% | -181.66% |
| Earnings before Tax (EBT) 1 | - | -98.15 | -201 | -247.8 | -204.9 |
| Net income 1 | -40.95 | -98.15 | -200.9 | -247.7 | -204.9 |
| Net margin | - | - | - | -19,898.03% | -191.94% |
| EPS 2 | -104.3 | -16.53 | -4.820 | -5.301 | -4.540 |
| Free Cash Flow 1 | - | -89.44 | -189.9 | -213.1 | -188.5 |
| FCF margin | - | - | - | -17,112.72% | -176.55% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 01/09/23 | 21/03/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -28.71 | -34.96 | -40.81 | -48.29 | -55.5 | -66.37 | -53.55 | -59.1 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -35.47 | -32.08 | -35.81 | -45.92 | -53.32 | -65.58 | -53.55 | -59.1 |
| Net income 1 | -35.47 | -32.08 | -35.81 | -45.92 | -53.32 | -65.58 | -53.55 | -59.1 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -47.37 | -1.490 | -0.8700 | -1.121 | -1.283 | -1.539 | -1.165 | -1.295 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 13/12/23 | 21/03/24 | 14/05/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -89.4 | -190 | -213 | -188 |
| ROE (net income / shareholders' equity) | - | -53% | -61.3% | -83% | - |
| ROA (Net income/ Total Assets) | - | -42.4% | -51.1% | -63.5% | - |
| Assets 1 | - | 231.6 | 393.3 | 390.3 | - |
| Book Value Per Share | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - |
| Capex 1 | - | 8.28 | 6 | 6.33 | 7 |
| Capex / Sales | - | - | - | 508.7% | 6.56% |
| Announcement Date | 01/09/23 | 21/03/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
16.72
USD
Average target price
31.33
USD
Spread / Average Target
+87.40%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -27.78% | 66Cr | |
| +40.80% | 5.37TCr | |
| +35.79% | 3.89TCr | |
| -8.05% | 3.88TCr | |
| -8.98% | 2.73TCr | |
| +10.69% | 2.59TCr | |
| -16.21% | 2.03TCr | |
| +31.00% | 1.28TCr | |
| +28.51% | 1.22TCr | |
| -1.67% | 1.2TCr |
- Stock Market
- Equities
- CRGX Stock
- Financials CARGO Therapeutics, Inc.
